Last reviewed · How we verify
Placebo Atazanavir
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials for HIV infection.
At a glance
| Generic name | Placebo Atazanavir |
|---|---|
| Also known as | Placebo group, Reyataz, BMS-232632 |
| Sponsor | Hospital do Coracao |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease (HIV) |
| Phase | Phase 3 |
Mechanism of action
Placebo Atazanavir contains no active drug substance and produces no direct molecular or therapeutic effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of active atazanavir treatment by comparison against an inert formulation.
Approved indications
- Control arm in phase 3 clinical trials for HIV infection
Common side effects
Key clinical trials
- Antiviral Agents Against COVID-19 Infection (PHASE2, PHASE3)
- Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (PHASE3)
- Study to Evaluate a HIV Drug for the Treatment of HIV Infection (PHASE2)
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
- Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (PHASE3)
- Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (PHASE3)
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults (PHASE3)
- Interaction With HIV Antiretroviral Agents (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Atazanavir CI brief — competitive landscape report
- Placebo Atazanavir updates RSS · CI watch RSS
- Hospital do Coracao portfolio CI